Congress Materials – Rheumatology Winter Clinical Symposium (RWCS 2026)
2026 Rheumatology Winter Clinical Symposium | Feb 11-14 | Maui, HI
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
12-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease, Alexis Ogdie, John Tesser, Timothy P. Fitzgerald, Elizabeth Adamson, Soumya D. Chakravarty, Robert R. McLean, Taylor S. Blachley, Melissa Eliot, Skyler S. Peterson, Aaron Broadwell, Kurt Oelke, Arthur Kavanaugh, Joseph F. Merola
Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results From APEX
Christopher T. Ritchlin, Philip J. Mease, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Steven Fakharzadeh, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis and Inadequate Response/Intolerance to One Prior Tumor Necrosis Factor Inhibitor Through 1 Year of the SOLSTICE Study
Alice B. Gottlieb, Joseph F. Merola, Phillip J Mease, Christopher T Ritchlin, Jose U Scher, Kimberly Parnell Lafferty, Soumya D Chakravarty, Yanli Wang, Yevgeniy Krol, Stacey Fitch, Alexis Ogdie
Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Targeted Synthetic Disease-modifying Antirheumatic Drugs
Philip J Mease, Jessica Walsh, Timothy P Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Pavithra Srinivas, Bruno Emond, Arthur Voegel, Yuxi Wang, Sinia Sareen, Helena Huang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F Merola
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.